The Low DoseThe GLP-1 price desk
Briefing

Eden vs MEDVi

$298/mo against $399/mo for tirzepatide. Which is worth it, and for whom.

Illustration of two objects on a balance scale

Updated 2026-09-18

Both sell tirzepatide. Eden costs $298 a month and MEDVi costs $399, a difference of $101 a month or about $1,212 a year. The desk reads it as follows.

Eden is low advertised medication price. MEDVi is tablet and injection choice. They are not aimed at the same person, and the cheaper one is not automatically the right answer — though on this board it usually is.

Advert against bill. Eden advertises $199 and bills $298; MEDVi advertises $399 and bills $399. The gaps are different sizes, which means comparing the two on their advertised prices gives you the wrong answer.

Side by side

EdenMEDVi
Advertised$199$399
Billed$298$399
Gap+$99none
Per year, billed$3,576$4,788

Prices verified 2026-09-18. "True monthly cost" is what you are billed in month two, once any introductory rate has lapsed and any membership has renewed.

The split

2 differences on the record. The others match.

EdenMEDVi
Price is the same at every doseYesNo
Offers an oral or sublingual optionNoYes

What each puts on the record: Eden

  • True ongoing cost for tirzepatide lands near $298/month once membership is included.

Where it wins: Genuinely low medication-only pricing. Watch for: The $99 semaglutide headline becomes roughly $198/month once the membership renews at its ongoing rate.

What each puts on the record: MEDVi

    Where it wins: Injection pricing is consistent between the first month and renewals. Watch for: You have to complete intake before seeing tablet pricing. Injection pricing is published at $399.

    In each one’s favour

    Eden.

    • Genuinely low medication-only pricing.
    • Fast onboarding with flat rates across published dose ranges.

    MEDVi.

    • Injection pricing is consistent between the first month and renewals.
    • Tablet option for people who will not inject.

    Eden scores higher overall at 3.1 out of 5. The weights are published on how we rate, and so is the note about which of these is our paid featured partner.

    The desk’s call

    The board says Eden. What the board cannot say is whether the advertised figures you were shown elsewhere match these — check the gap row, because a listing that advertises low and bills high will beat an honest one in any comparison built on advertised prices.

    The verdict

    On the board, Eden at $298 a month is the more defensible choice on arithmetic alone. MEDVi earns its premium only if you will actually use what it does differently. Read the full reviews before deciding: Eden and MEDVi.

    How they sit against everyone else

    ProgrammeAdvertisedBilledGapVs board floor
    Coreage Rx$149$199+$50+$74/mo
    Trimi$125$125none—
    Ozari Health$125$125none—
    Fifty 410$133$133none+$8/mo

    More from the desk

    • Eden tirzepatide review

      Advertised at $199, billed at $298. Position 11 of 18 on our board.

    • MEDVi tirzepatide review

      Advertised at $399 and billed at $399 — no gap. Position 14 of 18 on our board.

    • How to spot a bad seller

      The FDA sent more than 55 warning letters to online GLP-1 sellers in one day. Here is how to tell a licensed programme from the rest.

    • The twelve-month cost

      Month one is the cheapest month you will have. Here is the full-year arithmetic, including the costs nobody puts in the advert.

    • Cheapest right now

      Every programme sorted on what it bills, not what it advertises. Floor: $199/mo tirzepatide, $149/mo semaglutide.

    Coreage Rx pays us a commission on sign-ups through our links. It does not affect our scores or rankings. How we rate · Disclosure